New Era Energy & Digital, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $357.6M
- Price
- $2.96
- % Change (Daily % change from the live per-ticker quote feed.)
- +6.67%
- Volume
- 10.5M
About
New Era Energy & Digital, Inc. operates as an upstream energy company, specializing in the exploration, development, and production of a diverse range of resources. These include helium, crude oil, natural gas, and natural gas liquids (NGLs) across the United States. The company holds and develops a significant portfolio of approximately 137,000 acres situated in Southeast New Mexico. Its premier asset is the Pecos Slope Field, an expansive area covering 1893 square kilometers, located about 20 miles north of Roswell, New Mexico. New Era Energy & Digital primarily supplies its products to Tier 2 gas enterprises and distributors of balloon-grade helium. Headquartered in Midland, Texas, the company was formerly known as New Era Helium, Inc. and officially rebranded to New Era Energy & Digital, Inc. in August 2025.
Quick stats
Shares outstanding120.8M
Computed float67.2M
Float / shares55.6%
Cash runway (months)34.7
Key info
SectorTechnology
IndustrySoftware - Infrastructure
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0002028336
Websitehttps://www.newerainfra.ai
AI Summary
AI-generated1/50
minorneutrallegal litigation
Attention Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Erasca, Inc. (NASDAQ: ERAS); GPGI, Inc., f/k/a CompoSecure, Inc. (NYSE: GPGI); and New Era Energy & Digital, Inc. (NASDAQ: NUAI): Grabar Law Office is Investigating Claims on Your Behalf
Grabar Law Office announced investigations into claims on behalf of long-term shareholders of four issuers, including Aardvark Therapeutics (AARD), the primary ticker of this alert.
For AARD, the firm cites an already-filed securities class action alleging IPO-era documents overstated the safety of lead drug ARD-101, referencing the February 2026 Phase 3 HERO enrollment pause and the May 2026 full FDA clinical hold. No new company disclosure, court ruling, or settlement is contained in this release.
The release is attorney advertising seeking shareholder-plaintiffs, not an issuer announcement; it recaps previously public events and should be treated as low-signal noise.
Red flags
- Recaps material prior events already disclosed: HERO trial pause, full FDA clinical hold on ARD-101, ~56% and ~32% stock declines